This clinical trial is focused on studying the effects of two treatments for Multiple Sclerosis, a disease that affects the brain and spinal cord, leading to symptoms like fatigue, difficulty walking, and vision problems. The study compares the effectiveness and safety of a new medication called remibrutinib with an existing treatment known as teriflunomide. Participants will receive either remibrutinib or teriflunomide, and some may receive a placebo, which looks like the real medication but does not contain the active ingredient.
The purpose of the study is to determine if remibrutinib is better than teriflunomide in reducing the number of relapses, which are periods when symptoms of multiple sclerosis suddenly get worse. The study will begin with a period where participants are randomly assigned to receive either remibrutinib or teriflunomide. After this initial phase, all participants will have the opportunity to receive remibrutinib for an extended period. This approach helps researchers understand the long-term effects of remibrutinib on multiple sclerosis.
Throughout the study, participants will take their assigned medication by mouth, and their health will be monitored regularly. This includes checking for any new symptoms, changes in their condition, and any side effects from the medication. The study aims to provide valuable information about how well remibrutinib works compared to teriflunomide and to ensure the safety of participants while they are taking these medications.
Austria 
Belgium 
Bulgaria 
Croatia 
Denmark 
Ireland 
Italy 
Latvia 
Lithuania 
Poland 
Slovakia 
Spain 
The Netherlands 